0001104659-21-093670.txt : 20210719 0001104659-21-093670.hdr.sgml : 20210719 20210719210201 ACCESSION NUMBER: 0001104659-21-093670 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210114 FILED AS OF DATE: 20210719 DATE AS OF CHANGE: 20210719 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Esposito Pamela CENTRAL INDEX KEY: 0001744425 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 211099229 MAIL ADDRESS: STREET 1: C/O REPLIMUNE GROUP, INC. STREET 2: 18 COMMERCE WAY CITY: WOBURN STATE: MA ZIP: 01801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 4/A 1 tm2122438-3_4aseq1.xml OWNERSHIP DOCUMENT X0306 4/A 2021-01-14 2021-01-19 0 0001737953 Replimune Group, Inc. REPL 0001744425 Esposito Pamela C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK WOBURN MA 01801 0 1 0 0 Chief Business Officer Common Stock 2021-01-14 4 M 0 20000 1.01 A 195994 D Common Stock 2021-01-14 4 S 0 20000 45.02 D 175994 D Common Stock 2021-01-15 4 M 0 29273 1.01 A 205267 D Common Stock 2021-01-15 4 S 0 29273 43.58 D 175994 D Common Stock 2021-01-19 4 M 0 5727 1.01 A 181721 D Common Stock 2021-01-19 4 S 0 600 43.24 D 181121 D Common Stock 2021-01-19 4 S 0 5127 42.38 D 175994 D Employee Stock Option (right to buy) 1.01 2021-01-14 4 M 0 20000 0 D 2025-11-01 Common Stock 20000 108203 D Employee Stock Option (right to buy) 1.01 2021-01-15 4 M 0 29273 0 D 2025-11-01 Common Stock 29273 78930 D Employee Stock Option (right to buy) 1.01 2021-01-19 4 M 0 5727 0 D 2025-11-01 Common Stock 5727 73203 D The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.86. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.76. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Following the sales reported on this Form 4, the reporting person continues to beneficially own 175,994 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 458,852 shares of the Issuer's common stock, 284,936 of which are exercisable as of the date hereof. The original Form 4 filed on January 19, 2021 is being amended by this Form 4 solely to correct an administrative error, which misreported the total number of options held by the reporting person and the amount exercisable as of January 19, 2021. The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying such stock option have vested and are exercisable as of the date hereof. /s/ Jean Franchi, attorney-in-fact 2021-07-19